Your browser doesn't support javascript.
loading
Spatially clustering de novo variants in CYFIP2, encoding the cytoplasmic FMRP interacting protein 2, cause intellectual disability and seizures.
Zweier, Markus; Begemann, Anaïs; McWalter, Kirsty; Cho, Megan T; Abela, Lucia; Banka, Siddharth; Behring, Bettina; Berger, Andrea; Brown, Chester W; Carneiro, Maryline; Chen, Jiani; Cooper, Gregory M; Finnila, Candice R; Guillen Sacoto, Maria J; Henderson, Alex; Hüffmeier, Ulrike; Joset, Pascal; Kerr, Bronwyn; Lesca, Gaetan; Leszinski, Gloria S; McDermott, John Henry; Meltzer, Meira R; Monaghan, Kristin G; Mostafavi, Roya; Õunap, Katrin; Plecko, Barbara; Powis, Zöe; Purcarin, Gabriela; Reimand, Tiia; Riedhammer, Korbinian M; Schreiber, John M; Sirsi, Deepa; Wierenga, Klaas J; Wojcik, Monica H; Papuc, Sorina M; Steindl, Katharina; Sticht, Heinrich; Rauch, Anita.
Afiliação
  • Zweier M; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
  • Begemann A; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
  • McWalter K; Radiz-Rare Disease Initiative Zurich, Clinical Research Priority Program for Rare Diseases, University of Zurich, Zurich, Switzerland.
  • Cho MT; GeneDx, Gaithersburg, MD, USA.
  • Abela L; GeneDx, Gaithersburg, MD, USA.
  • Banka S; Radiz-Rare Disease Initiative Zurich, Clinical Research Priority Program for Rare Diseases, University of Zurich, Zurich, Switzerland.
  • Behring B; Division of Child Neurology, University Children's Hospital Zurich, Zurich, Switzerland.
  • Berger A; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
  • Brown CW; Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Carneiro M; Department of Pediatrics, Klinikum Nuremberg, Nuremberg, Germany.
  • Chen J; Department of Neuropediatrics, Klinikum Weiden, Kliniken Nordoberpfalz AG, Weiden, Germany.
  • Cooper GM; Le Bonheur Children's Hospital, Memphis, TN, USA.
  • Finnila CR; Department of Neuropediatrics, Lyon University Hospital, Lyon, France.
  • Guillen Sacoto MJ; University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Henderson A; HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
  • Joset P; HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
  • Kerr B; GeneDx, Gaithersburg, MD, USA.
  • Lesca G; Northern Genetics Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 3BZ, UK.
  • Leszinski GS; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • McDermott JH; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
  • Meltzer MR; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
  • Monaghan KG; Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Mostafavi R; Department of Medical Genetics, Lyon University Hospital, Lyon, France.
  • Õunap K; CNRS UMR 5292, INSERM U1028, Claude Bernard Lyon 1 University, Lyon, France.
  • Plecko B; Institute of Human Genetics, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Powis Z; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
  • Purcarin G; Children's National Health System, Washington, DC, USA.
  • Reimand T; GeneDx, Gaithersburg, MD, USA.
  • Riedhammer KM; Le Bonheur Children's Hospital, Memphis, TN, USA.
  • Schreiber JM; Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
  • Sirsi D; Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia.
  • Wierenga KJ; Radiz-Rare Disease Initiative Zurich, Clinical Research Priority Program for Rare Diseases, University of Zurich, Zurich, Switzerland.
  • Wojcik MH; Division of Child Neurology, University Children's Hospital Zurich, Zurich, Switzerland.
  • Papuc SM; Division of General Pediatrics, Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria.
  • Steindl K; Ambry Genetics, Aliso Viejo, CA, USA.
  • Sticht H; University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Rauch A; Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
Eur J Hum Genet ; 27(5): 747-759, 2019 05.
Article em En | MEDLINE | ID: mdl-30664714
ABSTRACT
CYFIP2, encoding the evolutionary highly conserved cytoplasmic FMRP interacting protein 2, has previously been proposed as a candidate gene for intellectual disability and autism because of its important role linking FMRP-dependent transcription regulation and actin polymerization via the WAVE regulatory complex (WRC). Recently, de novo variants affecting the amino acid p.Arg87 of CYFIP2 were reported in four individuals with epileptic encephalopathy. We here report 12 independent patients harboring a variety of de novo variants in CYFIP2 broadening the molecular and clinical spectrum of a novel CYFIP2-related neurodevelopmental disorder. Using trio whole-exome or -genome sequencing, we identified 12 independent patients carrying a total of eight distinct de novo variants in CYFIP2 with a shared phenotype of intellectual disability, seizures, and muscular hypotonia. We detected seven different missense variants, of which two occurred recurrently (p.(Arg87Cys) and p.(Ile664Met)), and a splice donor variant in the last intron for which we showed exon skipping in the transcript. The latter is expected to escape nonsense-mediated mRNA decay resulting in a truncated protein. Despite the large spacing in the primary structure, the variants spatially cluster in the tertiary structure and are all predicted to weaken the interaction with WAVE1 or NCKAP1 of the actin polymerization regulating WRC-complex. Preliminary genotype-phenotype correlation indicates a profound phenotype in p.Arg87 substitutions and a more variable phenotype in other alterations. This study evidenced a variety of de novo variants in CYFIP2 as a novel cause of mostly severe intellectual disability with seizures and muscular hypotonia.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Convulsões / Citoplasma / Proteínas Adaptadoras de Transdução de Sinal / Deficiência Intelectual / Mutação Tipo de estudo: Prognostic_studies Limite: Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Convulsões / Citoplasma / Proteínas Adaptadoras de Transdução de Sinal / Deficiência Intelectual / Mutação Tipo de estudo: Prognostic_studies Limite: Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article